Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: Results of a European cross-sectional observational study

Journal of Dermatological Treatment

Volumn 24, Issue 3, 2013, Pages 193-198

  Christophers, Enno ^a   Segaert, Siegfried ^b   Milligan, Gary ^c   Molta, Charles T ^d   Boggs, Robert ^d  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c ADELPHI REAL WORLD   (United Kingdom)

^d PFIZER INC   (United States)

Author keywords

Biological products; Disease management; Effectiveness; Patient satisfaction; Psoriasis

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMARIC ACID DERIVATIVE; INFLIXIMAB; METHOTREXATE;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CLINICAL ASSESSMENT; CROSS-SECTIONAL STUDY; DERMATOLOGIST; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT SATISFACTION; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; SYSTEMIC THERAPY; TOPICAL TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; BIOLOGICAL AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PHOTOTHERAPY; PSORIASIS; TREATMENT OUTCOME;

EID: 84877021380     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2012.697112     Document Type: Article

References (42)

1. Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Arch Dermatol. 2005;141:1537-1541.
2. Lebwohl M. Psoriasis. Lancet. 2003;361:1197-1204.
3. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136-139.
4. Tristani-Firouzi P, Krueger GG. Efficacy and safety of treatment modalities for psoriasis. Cutis. 1998;61(2 Suppl):11-21.
5. Lebwohl M. Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J Am Acad Dermatol. 2000;43 (2 Pt 3):S43- SS6.
6. Wollina U, Stander K, Barta U. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis- short- and long-term toxicity in 104 patients. Clin Rheumatol. 2001;20:406-410.
7. Grossman RM, Chevret S, Abi-Rached J, et al. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol. 1996;132: 623-629.
8. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139: 1627-1632.
9. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-2022.
10. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-1312.
11. Bansback N, Sizto S, Sun H, et al. Efficacy of systemic treatments for moderate to severe plaque psoriasis: Systematic review and metaanalysis. Dermatology. 2009;219:209-218.
12. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:31; e1-15.
13. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534-542.
14. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet. 2005;366:1367-1374.
15. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598-606.
16. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558-566.
17. Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: Results of a randomized phase III trial. Br J Dermatol. 2005;153:1192-1199.
18. Feldman SR, Kimball AB, Krueger GG, et al. Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial. J Am Acad Dermatol. 2005;53: 887-889.
19. Feldman SR, Gordon KB, Bala M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: A double-blind placebo-controlled trial. Br J Dermatol. 2005; 152:954-960.
20. Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: A randomized controlled trial. Br J Dermatol. 2006;154:1161-1168.
21. Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology. 2003;206:307-315.
22. Shikiar R, Heffernan M, Langley RG, et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: Patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat. 2007;18:25-31.
23. Brunasso AM, Puntoni M, Salvini C, et al. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: A study of 103 Italian patients. Acta Derm Venereol. 2011;91:44-49.
24. Saccomani C, Penz S, Guerre-Schmidt R, et al. Biological therapy for psoriasis: Practical experience at a French dermatology unit. Ann Dermatol Venereol. 2009;136:877-882.
25. Berends MA, Driessen RJ, Langewouters AM, et al. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. J Dermatol Treat. 2007;18:76-83.
26. De Groot M, Appelman M, Spuls PI, et al. Initial experience with routine administration of etanercept in psoriasis. Br J Dermatol. 2006; 155:808-814.
27. Mazzotta A, Esposito M, Costanzo A, Chimenti S. Efficacy and safety of etanercept in psoriasis after switching from other treatments: An observational study. Am J Clin Dermatol. 2009;10:319-324.
28. Antoniou C, Stefanaki I, Stratigos A, et al. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre. Br J Dermatol. 2010;162:1117-1123.
29. Warren RB, Brown BC, Lavery D, et al. Biologic therapies for psoriasis: Practical experience in a U.K. tertiary referral centre. Br J Dermatol. 2009;160:162-169.
30. Warren RB, Brown BC, Lavery D, Griffiths CE. Adalimumab for psoriasis: Practical experience in a U.K. tertiary referral centre. Br J Dermatol. 2010;163:859-862.
31. Anderson P, Benford M, Harris N, et al. Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. Curr Med Res Opin. 2008;3063-3072.
32. ESOMAR. Professional Standards. 2011. Available from http://www. esomar.org/index.php/professional-standards.html.Cited 27 Jan 2011.
33. US Department of Health and Human Services - National Institutes of Health. Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. 2007. Available from http://privacyruleandresearch.nih. gov/default.asp.Cited 27 Jan 2011.
34. British Standards Institute. Data Protection Act 1998. 1998. Available from http://www.legislation.gov.uk/ukpga/1998/29/contents. Cited 27 Jan 2011.
35. The Market Research Society (MRS) Census and Geodemographics Group. Geodemographics Knowledge Base. 2011. Available from http: //www. geodemographics.org.uk/index.html?SESSID=jc7s9fc1etfchn b5ckj8of1b20.Cited 27 Jan 2011.
36. Barker J, Hoffmann M, Guillet G, et al. Infliximab Demonstrates Early and Sustained Superiority to Methotrexate in the Treatment of Moderate to Severe Plaque-Type Psoriasis: The RESTORE I Trial. Presented at: 18th Congress of the European Academy of Dermatology and Venereology; 7-11 October 2009; Berlin, Germany.
37. Christophers E, Barker JN, Griffiths CE, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24:548-554.
38. Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17:809-812.
39. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33:712-721.
40. Gordon K, Korman N, Frankel E, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol. 2006;54(3 Suppl 2):S101- SS11.
41. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349: 2004-2013.
42. Dauden E, Griffiths CE, Ortonne JP, et al. Improvements in patientreported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: The CRYSTEL study. J Eur Acad Dermatol Venereol. 2009;23:1374-1382.